Seres Therapeutics Inc
NASDAQ:MCRB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/FCFF
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Valuation Scenarios
If EV/FCFF returns to its Industry Average (15.1), the stock would be worth $4.24 (40% downside from current price).
| Scenario | EV/FCFF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 25.1 | $7.05 |
0%
|
| Industry Average | 15.1 | $4.24 |
-40%
|
| Country Average | 23.2 | $6.53 |
-7%
|
Forward EV/FCFF
Today’s price vs future free cash flow to firm
Peer Comparison
| Market Cap | EV/FCFF | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Seres Therapeutics Inc
NASDAQ:MCRB
|
67.4m USD | 25.1 | 11.8 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -211 184.9 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
360.5B USD | 23.4 | 86.1 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
182.2B USD | 27.5 | 23.6 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
159.9B USD | 18.1 | 18.8 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -531.1 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
107.5B USD | 31.2 | 27.2 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
72.5B USD | 13.5 | 16.1 | |
| NL |
|
argenx SE
XBRU:ARGX
|
40.6B EUR | 139.4 | 36.7 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -64.3 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
60.6B AUD | 20.5 | 29.3 |
Market Distribution
| Min | 0 |
| 30th Percentile | 15.4 |
| Median | 23.2 |
| 70th Percentile | 35.1 |
| Max | 3 178 983.5 |
Other Multiples
Seres Therapeutics Inc
Glance View
Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. The company is headquartered in Cambridge, Massachusetts and currently employs 333 full-time employees. The company went IPO on 2015-06-26. The firm is engaged in developing a class of biological drugs, which are designed to treat disease by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The firm's lead product candidate, SER-109, is designed to reduce further recurrences of Clostridioides difficle infection (CDI). The company is also developing therapeutics, such as SER-155, to specifically target infections and antimicrobial resistance. SER-155, a microbiome therapeutic candidate consisting of a consortium of cultivated bacteria, is designed to reduce incidences of gastrointestinal infections, bloodstream infections and graft versus host disease (GvHD) in patients receiving allogeneic hematopoietic stem cell transplantation (allo-HSCT). In addition, using its microbiome therapeutics platform, the Company is developing SER-287 and SER-301 to treat ulcerative colitis (UC).
